https://www.selleckchem.com/products/dmx-5084.html
We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12-22months from 10 European countries were randomized in a 331 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose o
Like
Comment
Share
